Higher Morbidity of Monogenic Inflammatory Bowel Disease Compared to the Adolescent Onset Inflammatory Bowel Disease
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: Monogenic inflammatory bowel disease (IBD) patients do not respond to conventional therapy and are associated with a higher morbidity. We summarized the clinical characteristics of monogenic IBD patients and com-pared their clinical outcomes to that of non-monogenic IBD patients.Methods: We performed a retrospective cohort study of all children ＜18 years old who were diagnosed with IBD between 2005 and 2016. A total of 230 children were enrolled. Monogenic IBD was defined as a presentation age less than 6 years old with confirmation of a genetic disorder. We subdivided the groups into monogenic IBD (n=18), non-monogenic very early-onset IBD (defined as patients with a presentation age ＜6 years old without a confirmed genetic disorder, n=12), non-monogenic IBD (defined as all patients under 18 years old excluding monogenic IBD, n=212), and severe IBD (defined as patients treated with an anti-tumor necrosis factor excluding monogenic IBD, n=92). We compared demographic data, initial pediatric Crohn disease activity index/pediatric ulcerative colitis activ-ity index (PCDAI/PUCAI) score, frequency of hospitalizations, surgical experiences, and height and weight under 3rd percentile among the patients enrolled.Results: The initial PCDAI/PUCAI score (p＜0.05), incidence of surgery per year (p＜0.05), and hospitalization per year (p＜0.05) were higher in the monogenic IBD group than in the other IBD groups. Additionally, the proportion of children whose weight and height were less than the 3rd percentile (p＜0.05 and p＜0.05, respectively) was also higher in the monogenic IBD group. Conclusion: Monogenic IBD showed more severe clinical manifestations than the other groups.
Abstract
Purpose: Monogenic inflammatory bowel disease (IBD) patients do not respond to conventional therapy and are associated with a higher morbidity. We summarized the clinical characteristics of monogenic IBD patients and com-pared their clinical outcomes to that of non-monogenic IBD patients.Methods: We performed a retrospective cohort study of all children ＜18 years old who were diagnosed with IBD between 2005 and 2016. A total of 230 children were enrolled. Monogenic IBD was defined as a presentation age less than 6 years old with confirmation of a genetic disorder. We subdivided the groups into monogenic IBD (n=18), non-monogenic very early-onset IBD (defined as patients with a presentation age ＜6 years old without a confirmed genetic disorder, n=12), non-monogenic IBD (defined as all patients under 18 years old excluding monogenic IBD, n=212), and severe IBD (defined as patients treated with an anti-tumor necrosis factor excluding monogenic IBD, n=92). We compared demographic data, initial pediatric Crohn disease activity index/pediatric ulcerative colitis activ-ity index (PCDAI/PUCAI) score, frequency of hospitalizations, surgical experiences, and height and weight under 3rd percentile among the patients enrolled.Results: The initial PCDAI/PUCAI score (p＜0.05), incidence of surgery per year (p＜0.05), and hospitalization per year (p＜0.05) were higher in the monogenic IBD group than in the other IBD groups. Additionally, the proportion of children whose weight and height were less than the 3rd percentile (p＜0.05 and p＜0.05, respectively) was also higher in the monogenic IBD group. Conclusion: Monogenic IBD showed more severe clinical manifestations than the other groups.
참고문헌 (26)
- Loddo I, "Inflammatory bowel disease: genetics, epigenetics, and pathogenesis", Front Immunol, 6, pp.551~ (2015)
- 서정기, "소아기에 발병하는 염증성장질환(IBD)은 성인 IBD와 다른 질환인가? - 조기발병 소아 IBD의 역학적, 임상적, 유전학적 특성 및 치료 시 고려 사항-", Pediatric Gastroenterology, Hepatology & Nutrition, 14(1), pp.1~25 (2011), 대한소아소화기영양학회
- Seo JK, "Inflammatory bowel disease in children: clinical, endoscopic, radiologic and histopathologic investigation", J Korean Med Sci, 7, pp.221~235 (1992)[DOI]
- Uhlig HH, "Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease", Gut, 62, pp.1795~1805 (2013)[DOI]
- Kotlarz D, "Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy", Gastroenterology, 143, pp.347~355 (2012)[DOI]
- Muise AM, "NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2", Gut, 61, pp.1028~1035 (2012)[DOI]
- Moran CJ, "IL-10R polymorphisms are associated with very-early-onset ulcerative colitis", Inflamm Bowel Dis, 19, pp.115~123 (2013)[DOI]
- Glocker EO, "Inflammatory bowel disease and mutations affecting the interleukin-10 receptor", N Engl J Med, 361, pp.2033~2045 (2009)[DOI]
- Ruemmele FM, "Characteristics of inflammatory bowel disease with onset during the first year of life", J Pediatr Gastroenterol Nutr, 43, pp.603~609 (2006)[DOI]
- Chouraki V, "The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007)", Aliment Pharmacol Ther, 33, pp.1133~1142 (2011)[DOI]
- Benchimol EI, "Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease", Gastroenterology, 147, pp.803~813 (2014)[DOI]
- Aloi M, "Phenotype and disease course of early-onset pediatric inflammatory bowel disease", Inflamm Bowel Dis, 20, pp.597~605 (2014)[DOI]
- "J Crohns Colitis", 2017, 519~526
- Gupta N, "Presentation and disease course in early- compared to later-onset pediatric Crohn's disease", Am J Gastroenterol, 103, pp.2092~2098 (2008)[DOI]
- Gower-Rousseau C, "The natural history of pediatric ulcerative colitis: a population-based cohort study", Am J Gastroenterol, 104, pp.2080~2088 (2009)[DOI]
- Imielinski M, "Common variants at five new loci associated with early-onset inflammatory bowel disease", Nat Genet, 41, pp.1335~1340 (2009)[DOI]
- Flores A, "Obesity in inflammatory bowel disease: a marker of less severe disease", Dig Dis Sci, 60, pp.2436~2445 (2015)[DOI]
- Glocker E, "Inflammatory bowel disease: is it a primary immunodeficiency?", Cell Mol Life Sci, 69, pp.41~48 (2012)[DOI]
- Glocker EO, "Infant colitis--it's in the genes", Lancet, 376, pp.1272~ (2010)[DOI]
- Bader-Meunier B, "Mevalonate kinase deficiency: a survey of 50 patients", Pediatrics, 128, pp.152~159 (2011)[DOI]
- van der Burgh R, "Mevalonate kinase deficiency, a metabolic autoinflammatory disease", Clin Immunol, 147, pp.197~206 (2013)[DOI]
- Galeotti C, "Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency", Rheumatology (Oxford), 51, pp.1855~1859 (2012)[DOI]
- Paul T, "Distinct phenotype of early childhood inflammatory bowel disease", J Clin Gastroenterol, 40, pp.583~586 (2006)[DOI]
- Mamula P, "Inflammatory bowel disease in children 5 years of age and younger", Am J Gastroenterol, 97, pp.2005~2010 (2002)[DOI]
- Tarrant KM, "Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype", Am J Gastroenterol, 103, pp.3082~3093 (2008)[DOI]
- Shaoul R, "Disease behavior in children with Crohn's disease: the effect of disease duration, ethnicity, genotype, and phenotype", Dig Dis Sci, 54, pp.142~150 (2009)[DOI]